Conference Summaries: Day Three<BR> Tuesday, February 1, 2000

The Body Covers: The 7th Conference on Retroviruses and Opportunistic Infections

Conference Summaries: Day Three
Tuesday, February 1, 2000

Session 56 -- State of the Art Lecture: Timing the Origin of the HIV Pandemic
Coverage by Melanie Thompson, M.D.
- L5: Timing the Origin of the HIV Pandemic
Session 61 -- Antiviral Therapy: Clinical Trials
Coverage by Paul Sax, M.D.
- Slide 452: CCR5 D32 Deletion and Response to HAART in HIV-1-Infected Patients
  For more on this abstract from Seattle Treatment Education Project, click here
- Slide 456: Randomized Trial of Continued Indinavir (IDV)/ZDV/3TC vs. Switch to IDV/ddI/d4T or IDV/ddI/d4T + Hydroxyurea in Patients with Viral Suppression
- Slide 457: Protease Inhibitor Class-Sparing Maintenance Therapy with Abacavir (ABC) + Lamivudine (3TC) + Zidovudine (ZDV) in Patients with Long-Term Suppression of HIV-1 RNA
  For more on this abstract from Seattle Treatment Education Project, click here
Coverage by Seattle Treatment Education Project
Session 62 -- Trends in HIV-Associated Mortality
Coverage by Melanie Thompson, M.D.
Session 67 -- Novel Antiretroviral Agents: Protease Inhibitors
Coverage by Paul Sax, M.D.
- Poster 504: BMS-232632: A Summary of Multiple Dose Pharmacokinetic, Food Effect and Drug Interaction Studies in Healthy Subjects
Session 68 -- Antiretroviral Therapy in Treatment-Naïve Patients
Coverage by Doug Ward, M.D.
- Poster 510: Preliminary Results of a Randomized Multicenter Study Comparing Combivir (ZDV/3TC) plus Nelfinavir or Nevirapine in HIV-Infected naïve Patients (COMBINE Study)
Coverage by Rick Stryker, M.D., M.P.H.
Coverage by Seattle Treatment Education Project
Session 69 -- Antiretroviral Chemotherapy: Treatment-Experienced Patients
Coverage by Doug Ward, M.D.
- Poster 525: Continued Lamivudine (3TC) vs. Delavirdine (DLV) in Combination with Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Patients: 48-Week Follow-Up of ACTG 370
- Poster 526: Indinavir (IDV), Nevirapine (NVP), Stavudine (d4T) and Lamivudine (3TC) for Amprenavir (APV)-Experienced Subjects -- ACTG 373
Coverage by Melanie Thompson, M.D.
Coverage by Seattle Treatment Education Project
Session 70 -- Immune-Based and Genetic Therapies
Coverage by Mark Holodniy, M.D.
- Poster 543: ILSTIM (ANRS 082): A Randomized Comparative Open-Label Study of Interleukin (IL2) in Patients with CD4 <200/mm³ Despite Effective HAART
Session 74 -- Treatment of Primary Infection
Coverage by Mark Holodniy, M.D.

STEP Conference Coverage

Hear the Lectures from The 7th Conference on Retroviruses and Opportunistic Infections

Hear the Symposia from The 7th Conference on Retroviruses and Opportunistic Infections

Browse or search the abstracts

Return to The Body's coverage of
The 7th Conference on Retroviruses and Opportunistic Infections.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.